Sweet syndrome-like cutaneous drug reaction*
نویسندگان
چکیده
Cutaneous drug reactions are adverse reactions to medications that may present with different clinical features, ranging from localized to generalized lesions. In this report we describe a case of an unusual drug reaction, resembling the morphology of Sweet syndrome lesions. The patient had a psychiatric illness and was using thioridazine hydrochloride for one year. He developed infiltrated and grouped erythematous lesions on the elbows and knees three days after commencing multiple drugs (promethazine, haloperidol, mirtazapine and levomepromazine). After suspension of these four drugs and after the use of glucocorticoids, the patient had significant clinical improvement.
منابع مشابه
Drug-associated histiocytoid Sweet's syndrome: a true neutrophilic maturation arrest variant.
Histiocytoid Sweet's syndrome is a recently described entity which has clinical features identical to typical Sweet's syndrome but is distinguished by a dermal cellular infiltrate composed not of mature neutrophils but of immature granulocytes. Herein, we report a case of bone marrow granulocytic maturation arrest and a histological histiocytoid Sweet's-like reaction pattern following trimethop...
متن کاملEditorial comment: Sweet syndrome--a diagnosis seeking a cause.
Dermatological disorders may occur in more than 90% of persons infected with HIV. In this setting, skin disorders tend to be more frequent as immunodeficiency progresses. The spectrum of cutaneous diseases includes inflammatory dermatoses, drug reactions, infections, and neoplasms. Johnson and colleagues1 present an unusual case of Sweet syndrome in a 37-year-old HIV-positive man coinfected wit...
متن کاملAzathioprine hypersensitivity presenting as sweet syndrome in a child with ulcerative colitis.
Sweet syndrome is a cutaneous lesion characterized by tender, red inflammatory nodules or papules. We describe a pediatric case of Sweet syndrome presenting 10 days after treatment with azathioprine. As azathioprine is widely used in children with inflammatory bowel disease, clinicians should be aware of this unusual adverse reaction.
متن کاملImatinib mesylate-induced lichenoid drug eruption.
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes t...
متن کاملEpidemiology of Severe Cutaneous Adverse Drug Reaction and Its HLA Association among Pediatrics
Severe cutaneous adverse drug reaction (SCAR) is considered to be a multifactorial drug side effect. This study was designed to investigate the epidemiology and human leukocyte antigen (HLA)-A and -B gene polymorphisms in pediatric patients with SCAR admitted in tertiary referral center, southwestern of Iran from 2013 to 2017. Demographic data, past allergy and autoimmune history, clinical pres...
متن کامل